1. Scrip
  2. >>Therapy Areas

Pre-emptive litigation in India: "extra-cautionary" or backdoor patent linkage?

 
• By Anju Ghangurde

Is the surge in pre-emptive litigation by innovator companies in India simply part of "extra cautionary" steps to rein in infringement attempts by generic firms or is there more at play?

Is the surge in pre-emptive litigation by innovator companies in India simply part of "extra cautionary" steps to rein in infringement attempts by generic firms or is there more at play?

Scrip has contacted a clutch of legal experts, some of whom suggested that while innovator firms' actions may be justifiable...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.